EurekAlert! -
9 Feb 2021 07:00
(Georgia State University) The drug is effective at treating pancreatic cancer and prolonging survival in mice, according to a study published in the journal Cellular and Molecular Gastroenterology and Hepatology. A second study, published in the Journal of Experimental Medicine, shows the drug is also effective against triple-negative breast cancer, a fast-growing and hard-to-treat type of breast cancer that carries a poor prognosis. Clinical trials are set to begin in 2021.
Share this Article